TY  - JOUR
AU  - Nishio, Makoto
AU  - Barlesi, Fabrice
AU  - West, Howard
AU  - Ball, Simon
AU  - Bordoni, Rodolfo
AU  - Cobo, Manuel
AU  - Longeras, Pascale Dubray
AU  - Goldschmidt, Jerome
AU  - Novello, Silvia
AU  - Orlandi, Francisco
AU  - Sanborn, Rachel E
AU  - Szalai, Zsuzsanna
AU  - Ursol, Grigoriy
AU  - Mendus, Diana
AU  - Wang, Lijia
AU  - Wen, Xiaohui
AU  - McCleland, Mark
AU  - Hoang, Tien
AU  - Phan, See
AU  - Socinski, Mark A
PY  - 2020
DO  - 10.1016/j.jtho.2020.11.025
UR  - http://hdl.handle.net/10668/16813
T2  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
AB  - We report the final results of the phase 3 IMpower132 study evaluating atezolizumab plus carboplatin or cisplatin plus pemetrexed (APP) in patients with nonsquamous NSCLC. Chemotherapy-naive patients with stage IV nonsquamous NSCLC without sensitizing...
LA  - en
PB  - Elsevier
KW  - Atezolizumab
KW  - Lung cancer
KW  - Nonsquamous
KW  - Non–small cell
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carboplatin
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Cisplatin
KW  - Humans
KW  - Lung Neoplasms
KW  - Pemetrexed
TI  - Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
TY  - research article
VL  - 16
ER  -